Alexandria Real Estate Equities
AREBusiness Overview
ticker: ARE step: 01 generated: 2026-05-13 source: quick-research
Alexandria Real Estate Equities, Inc. (ARE) — Business Overview
Business Description
Alexandria Real Estate Equities is the pioneer and dominant operator of life science mega-campus real estate in the United States. Founded in 1994, Alexandria invented the concept of mission-critical lab and research campuses co-located in the world's most productive biotech innovation clusters — Cambridge/Boston, San Francisco Bay Area, San Diego, Seattle, New York City, and Research Triangle Park (NC). As of December 31, 2024, the company owned or had investments in 391 properties containing 44.1 million square feet — by far the largest purpose-built life science real estate portfolio in the world. 74% of annual rental revenue derives from collaborative "mega campuses" in the top-tier innovation clusters.
Revenue Model
Revenue is generated from long-term leases (typically 10–15 years) with investment-grade pharmaceutical majors (Bristol-Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, Moderna) and high-profile biotech companies on purpose-built laboratory, R&D, and office space. Alexandria also co-invests in early-stage life science companies through its Alexandria Venture Investments platform, creating upside through equity stakes that grow as tenants scale. The mega-campus format generates above-market lease spreads because alternatives (generic office space) cannot accommodate lab-specific electrical, HVAC, and biosafety infrastructure.
Products & Services
- Mega Campuses: Purpose-built, clustered life science campuses in top innovation hubs — Cambridge, Mission Bay (SF), Torrey Pines (San Diego), Lake Union (Seattle), ARE NYC
- Tenant Mix: ~70% investment-grade or publicly traded biotech/pharma; ~30% venture-backed biotech (higher credit risk)
- Alexandria Venture Investments: Equity co-investments in biotech tenants; realized gains recognized on IPOs and acquisitions
- Development Pipeline: 1.9M SF under construction, 77% pre-leased (2025); ~80% of 2024–2025 pipeline pre-leased at delivery
Customer Base & Go-to-Market
ARE's 391-property portfolio is leased to the world's top pharmaceutical companies, biotechnology firms, genomics companies, and medical device manufacturers. Investment-grade or publicly traded tenants account for ~70% of revenue. No single tenant represents more than ~5% of annual base rent. The mega-campus model creates "cluster lock-in" — tenants co-locate with partners, suppliers, and talent pools, creating switching costs that make ARE's campuses far stickier than generic office space.
Competitive Position
Alexandria has no direct peer at scale — it is the only pure-play life science campus REIT in the S&P 500. Healthpeak (DOC/PEAK) has life science exposure but is primarily medical office. The combination of proprietary campus infrastructure, regulatory expertise, and cluster relationships creates a network effect moat: the best biotech companies want to be in ARE's Cambridge and Mission Bay campuses because proximity to other innovators accelerates research productivity. This moat was constructed over 30 years and cannot be replicated quickly.
Key Facts
- Founded: 1994
- Headquarters: Pasadena, CA
- Employees: ~600
- Exchange: NYSE
- Sector / Industry: Real Estate / Specialized REITs
- Market Cap: ~$16B
Financial Snapshot
ticker: ARE step: 04 generated: 2026-05-13 source: quick-research
Alexandria Real Estate Equities, Inc. (ARE) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | ~$2.59B | ~$2.89B | $3.12B | +8.0% |
| NOI Margin | ~65% | ~64% | ~63% | |
| FFO as Adjusted (total) | ~$1.55B | ~$1.63B | ~$1.72B | +5.5% |
| FFO/Share as Adjusted | $8.42 | $8.97 | $9.47 | +5.6% |
| Net Income/Share | $3.18 | $0.54 | $1.80 |
FY2025 FFO/share as adjusted: $9.01 (actual). FY2025 GAAP net loss/share: -$8.44 — driven by $1.45B in impairment charges on lab assets reflecting the life science market downturn.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| FFO as Adjusted | ~$1.72B |
| Annual Dividend | ~$5.24/share annualized (~4.5% yield) |
| Total Debt | ~$13.0B |
| Liquidity | $4.2B (one of strongest in REIT sector) |
| Average Debt Maturity | ~10 years (longest among S&P 500 REITs) |
| FY2025 Impairment Charges | $1.45B (non-cash; reflects lab market value reset) |
$4.2B liquidity and 10-year average debt maturity make ARE one of the most conservatively financed large REITs — critical given the current lab market dislocation.
Key Ratios (approximate)
- Price/FFO as Adjusted: ~12x | Implied Cap Rate: ~6.5% | Dividend Yield: ~4.5%
- Same-Property NOI Growth (FY2024): +1.2% (GAAP), +4.6% (cash basis)
- Q1 2026 FFO/share as Adjusted: $1.73 (strong; questioning bearish cash flow narratives)
- Leased % (2025): 87.7%–89.3% projected for year-end 2026
Growth Profile
Alexandria delivered consistent 5–8% FFO/share growth from FY2022–FY2024 driven by long-term lease escalators and development deliveries. FY2025 marked a painful inflection: $1.45B in non-cash impairment charges (reflecting lab market value reset) produced a GAAP net loss/share of -$8.44, though FFO as Adjusted of $9.01/share remained solid. The life science market — having grown lab supply 7.5x since 2021 while demand dropped 60% — entered a prolonged vacancy cycle with 30%+ vacancy in Boston and SF. Recovery is projected for Cambridge/Watertown/Seaport in 2–3 years.
Forward Estimates
- FY2026 FFO guidance: 87.7%–89.3% leased at year-end; FFO/share trajectory flat to slightly down vs. FY2025
- 1.9M SF under construction, 77% pre-leased — expected to stabilize in 2026 at 93% leased
- 1.2M SF of 2026 lease expirations in Boston/SF/SD — expected 6–24 month re-lease periods
- Long-term recovery: Cambridge, Mission Bay, and Seaport markets expected to recover in 2–3 years per management
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $ARE.